FDA Inspection
Carie Boyd Pharmaceuticals LLCCarie Boyd Pharmaceuticals LLC – FDA Inspection, Sep 8, 2026
Record Details
This FDA Inspection record concerns Carie Boyd Pharmaceuticals LLC, with an inspection on September 8, 2026, issued by the Dallas District Office, covering human drugs.
View Company Profile
ID · cafbcd7d-0543-4bd0-bec6-2991e862ecc2
Inspection Facts
- Inspection number
- 1334806
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
6- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.160(b)(4)Test devices not meeting specifications
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Carie Boyd Pharmaceuticals LLC
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 18, 2025 | Not classified | Dallas District Office | Drug Quality Assurance |
| June 21, 2024 | OAI | Drug Quality Assurance | |
| June 27, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 12, 2019 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 12, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Carie Boyd Pharmaceuticals LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.